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ABSTRACT
Background and objectives: about 1%-2% of patients with chronic refractory pouchitis, in
the context of ulcerative colitis, end up with a permanent ileostomy. The aim of this
systematic review was to collect all published studies involving patients treated with
vedolizumab for chronic refractory or antibiotic-dependent pouchitis and then pool the data
regarding the effectiveness of this therapeutic strategy.
Methods: a MEDLINE and Web of Science search of all studies published in English until
March 17, 2019 was conducted using the terms “vedolizumab and pouchitis”.
Results: seven studies with a total of 44 patients with chronic pouchitis were included.
Twenty-three out of 44 patients (52.3%) had undergone previous treatment with anti-tumor
necrosis factor (TNF) drugs. At week 12, 33 out of 44 patients (75%) reported clinical
improvement. Endoscopic improvement, evaluated within 6 months of the start of
vedolizumab therapy, was obtained in 28 out of the 38 patients in whom such data were
available (73.7%).
Conclusions: this first systematic review published in the literature on this issue suggests
that vedolizumab has significant efficacy in chronic refractory or antibiotic-dependent
pouchitis, also in patients who failed to respond to other treatments including those with
anti-TNF agents.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by bloody
diarrhoea, abdominal cramps, and fatigue (1). Since in the last decades its therapy has been
notably improved, UC has shifted from being a disease with high mortality rates, in case of
severe flare-ups, to a disease for which numerous classes of drugs are available, including
mesalazine, corticosteroids, monoclonal antibodies, and so-called small molecules (2).
Unfortunately, even today 10% to 15% of patients with UC require surgery either after failing
to respond to medical therapy or because of their developing dysplasia. The surgical
treatment of choice for most of these patients is proctocolectomy with ileal pouch-anal
anastomosis (IPAA) (3).
Despite the fact that UC is, by definition, a disease limited to the colon and rectum, in theory
healed by total proctocolectomy, many patients develop nonspecific inflammation in the
pouch, the so-called “pouchitis”, leading to symptoms such as pain, urgency, and increased
stool frequency, with estimated incidences ranging from 46% to 82% (4). The
pathophysiology of pouchitis remains poorly understood, despite its being the most
common long-term complication after IPAA. An increase in bacterial levels and dysbiosis in
the ileal reservoir seem to be among the main contributors (5). Inflammation of the pouch
after IPAA can significantly impact quality of life in these patients and could be difficult to
treat. Treatments for pouchitis include probiotics (6) (i.e., VSL#3) (7), antibiotics (i.e.,
ciprofloxacin, metronidazole), and topical therapy (8). However, about 10% to 15% of
patients with acute pouchitis do not respond to these treatments and develop chronic
pouchitis, which is defined by symptoms persisting for more than 4 weeks. These patients
often require rotating courses of antibiotics as well as maintenance therapy. Steroids (i.e.,
budesonide) (9), immunosuppressants (i.e., azathioprine) (10), and anti-tumor necrosis
factor (TNF) (i.e., infliximab, adalimumab) agents (11,12) are some of the options used to
treat chronic pouchitis. Studies including small numbers of patients (often fewer than 20),
and mostly retrospective in design, have demonstrated that infliximab appears to have good
clinical effectiveness in selected patients with pouchitis, achieving up to 80% of short-term
and around 50% of long-term responses. However, some data suggest that, in some patients
treated with anti-TNF agents for chronic pouchitis, the result may potentially consist of a
delay for inevitable surgery rather than a meaningful impact on the course of disease (13). In
fact, with these drugs, 60%-80% of patients achieve a clinical response or remission, but 1%-
2% of them end up with a permanent ileostomy (14).
Thus, despite the introduction of biological therapies, many patients with pouchitis remain
refractory to available treatments, requiring surgical excision of the pouch or permanent
diversion. There is, therefore, room for new therapeutic options in the patients who fail to
respond to commonly used drugs in order to try and avoid definitive ileostomy. In this
regard, the potential role of bacteria in the pathogenesis of pouchitis, confirmed both by the
efficacy of antibiotic treatment during active pouchitis and the benefit induced by using
probiotics in the maintenance of remission, has opened the way to one of the newer
biological drugs approved for UC, vedolizumab. Dysbiosis, defined as an unfavourable
alteration of the quantitative and qualitative composition of intestinal microbiota,
contributes to the attraction of leucocyte adhesion by integrin-MAdCam interaction (15).
Vedolizumab is a gut-selective, humanized monoclonal antibody of the immunoglobulin G1
type against alpha 4-beta 7 integrin, moderating gut lymphocyte trafficking (blocking the link
between alpha 4-beta 7 integrin and MAdCam), and is approved for the treatment of both
UC and Crohn’s disease.
To date, few studies are available about the efficacy of vedolizumab in the setting of chronic
pouchitis (16-18), and no systematic review has been published. The aim of this systematic
review is to collect all the published data about patients treated with vedolizumab for
chronic refractory pouchitis and to pool together those dealing with the effectiveness of this
therapeutic strategy.
METHODS
Articles published in English on the use of vedolizumab for the treatment of chronic
refractory pouchitis were identified through PubMed and Web of Science (“All databases”)
searches using the terms “vedolizumab and pouchitis”. The final date of the search was
March 17, 2019.
Reference lists from published articles were also employed, such as citing articles on
PubMed Central. The titles of these publications and their abstracts were scanned in order
to eliminate duplicates and irrelevant articles.
The inclusion criteria were:
a) confirmed diagnosis of UC subjected to proctocolectomy with IPAA;
b) use of vedolizumab treatment for chronic refractory antibiotic-dependent pouchitis;
c) availability of data about age, gender, percentage of patients treated with an anti-
TNF for pouchitis, and percentage of clinical (as defined in each case report and case
series) and endoscopic response.
The exclusion criteria were:
a) Crohn’s disease of the pouch;
b) review articles.
There was no restriction regarding study design type or sample size.
Two authors (D.G.R. and R.P.) independently reviewed the titles and abstracts of the
references retrieved by the literature search, and selected the potentially relevant studies.
The full-text version of the selected studies was then assessed by the two authors to
determine whether the inclusion criteria were met. Differences in opinion were solved by
discussion until consensus was reached. If agreement failed to be reached, a third author
(A.M.) was consulted.
Since only retrospective case series and case reports regarding vedolizumab efficacy in
chronic refractory pouchitis without a comparator are available in the literature, all the
studies in agreement with the inclusion and exclusion criteria were included in the
systematic review and in the pooled analysis, without a quality analysis of each study or a
meta-analysis.
Statistical analysis
The number of patients, their age and gender, the use of anti-TNF drugs for pouchitis, and
data related to clinical and endoscopic improvement were collected in a datasheet and pool
analysed.
Data were tested for normality using the D’Agostino-Pearson test. If these were not normally
distributed, the median (range) was reported, otherwise the mean (range) was reported.
Categorical variables were reported as number and percentage.
The statistical analysis was conducted using the MedCalc Statistical Software version 18.9.1
(MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018).
RESULTS
Figure 1 represents a flow diagram showing study parameters such as identification,
screening, eligibility, and number of included studies.
In the year 2017, Schmid et al. published the first case report of a pouchitis treated with
vedolizumab (16). A 54-year-old male with a history of IPAA for refractory UC developed
pouchitis 14 years later. Pouchitis was refractory to treatment with metronidazole, VSL#3,
budesonide, mesalamine, hydrocortisone rectal foam, and finally faecal microbiota
transplantation. The patient was switched to vedolizumab therapy and showed sustained
clinical and endoscopic responses (after 6 months from the start of treatment) (Table 1).
In the same year, Coletta et al. published a case report regarding a 33-year-old man with
anti-TNF-refractory chronic pouchitis treated with vedolizumab (17). The patient, due to
unresponsiveness to medical management, eventually underwent IPAA. As soon as 3 months
after ileostomy closure chronic pouchitis developed; it was refractory to antibiotics and anti-
TNF agents. Thus, vedolizumab was started leading to a marked clinical improvement, which
was maintained up to the end of follow-up (week 34). Compared with baseline, an
endoscopy performed at week 14 documented a complete resolution of erosions and
ulcerations.
Mir et al. published the case of a 41-year-old female who underwent IPAA due to refractory
UC (18). Two years after IPAA the patient developed pouchitis and was treated firstly with
trimethoprim-sulfamethoxazole and then with rifaximin, obtaining a partial response (stool
blood resolved but she continued to have from 10 to 20 bowel movements daily). After
initiation of vedolizumab clinical improvement was reported at week 6, with a decreased
frequency of bowel movements to four to six daily without stool blood. Abdominal pain also
improved. A repeat pouchoscopy demonstrated only a single linear ulcer and a healthy
pouch mucosa after 6 months from the initiation of vedolizumab.
In 2018, Martins et al. published a case report regarding a 20-year-old woman who
underwent IPAA due to refractoriness to infliximab. One year later a relapsing chronic
pouchitis was diagnosed and treated with antibiotics and oral budesonide, obtaining a
partial response. Subsequently, adalimumab was started without remission. Hence, the
authors employed vedolizumab. With the latter agent the patient reported clinical
improvement at week 12, and a pouchoscopy performed after 6 months on treatment
revealed only mucosal oedema (19).
Orfanoudaki et al. published a case report about a 22-year-old female with a history of IPAA
due to refractory UC. The patient was diagnosed with pouchitis 1 year after surgery. Initially,
she was treated with antibiotics and prednisolone, then with infliximab followed by
adalimumab, both discontinued after an early severe allergic reaction and a loss of response
attributed to antibody formation, respectively. Vedolizumab was subsequently initiated,
together with a single course of antibiotics, and the patient experienced clinical
amelioration. A new pouchoscopy, performed at week 33, showed significant improvement,
with scars and small ulcerations (20).
Bär et al. published the first retrospective case series about the efficacy of vedolizumab in
the treatment of chronic and antibiotic-dependent or refractory pouchitis (21). The authors
included 20 patients, of whom 12 men, with a median age of 22.5 years; all of them
underwent IPAA due to refractory UC (median duration from IPAA to pouchitis: 1 year).
Eleven patients had experienced at least one treatment with anti-TNF agents for pouchitis.
All patients were treated with vedolizumab, and at week 14 clinical improvement was
achieved in 13 out of 20 of them. In 14 patients the endoscopic outcome was assessed at
week 14, with a response being achieved in 9 of them. The pouch disease activity index
(PDAI), a validated score used to assess the endoscopic effectiveness of a drug, dropped
from 10 to 3 (normal range, 0-18).
Another retrospective case series was published in the year 2018. This study included 4
patients previously described in the first case series published about vedolizumab efficacy in
refractory chronic pouchitis (22), and a total of 19 patients were analysed (23). Ten of them
were male and the mean age of the cohort was 26.7 years. Nine patients were treated with
anti-TNF agents after colectomy and IPAA. Fifteen patients had at least a clinical response to
vedolizumab, 14 had both endoscopic and clinical responses, and 4 patients underwent
surgery because of drug therapy failure.
Pooled analysis
A total of 44 patients met the inclusion criteria of this systematic review. Mean age was 25.6
years; 24 patients were male (54.5%) and 20 were female (45.5%). Twenty-three out of 44
patients (52.3%) had a previous experience with anti-TNF agents for chronic pouchitis.
Clinical improvement at week 12 was obtained in 33 out of 44 patients (75%) (Fig. 2).
Endoscopic improvement, evaluated within 6 months of the start of vedolizumab therapy,
was obtained in 28 out of the 38 patients in whom data were available (73.7%) (Fig. 3).
DISCUSSION
As mentioned in the introduction, since dysbiosis is a key factor for pouchitis development,
and contributes to the attraction of leucocytes that will undergo adhesion by the integrin-
MAdCam interaction (15), vedolizumab, a drug that blocks alpha 4-beta 7 integrin, could be
a drug potentially effective in this setting. In theory, vedolizumab could represent a good
option for this unmet need but data on the treatment of chronic pouchitis with this drug are
limited as of today.
Our study represents the first systematic review with a pooled analysis focusing on the
effectiveness of vedolizumab in the treatment of chronic refractory pouchitis. We included 7
studies, of which 2 were retrospective case series and 5 were case reports, with a total of 44
patients. We excluded patients treated for Crohn’s disease of the pouch.
Regarding the epidemiological characteristics of the cohort treated so far, gender was
almost equally distributed (54.5% were male), and mean age was 25.6 years. Almost half of
these patients (52.3%) had been previously treated for chronic pouchitis with at least 1 anti-
TNF drug, after failure of conventional first-line therapies (probiotics, antibiotics,
budesonide).
Considering the difficulties entailed by the population treated, the 75% rate of clinical
improvement (as defined by each included study) and the 73.7% rate of endoscopic
improvement may be considered to be more than merely satisfactory. In addition to these
favourable results, a gut-specific anti-integrin therapy like vedolizumab has the benefit of
being potentially safer than systemic therapies, and could therefore be the ideal drug to be
used also for a maintenance strategy, which is often needed in these patients.
Since no comparative studies between vedolizumab and anti-TNF agents as salvage therapy
before definitive ileostomy in chronic pouchitis are available, vedolizumab (because of its
higher cost) should be positioned after anti-TNF drugs have failed or when their use is
contraindicated.
Increasing attention to the use of the newer biological agents and the possible incorporation
of future small-molecule therapies hold great promise in closing the remaining therapeutic
gap still present in the treatment of chronic pouchitis. Furthermore, an efficacious use of
vedolizumab would not only provide a significant therapeutic advance but would also offer
further insights into the underlying pathogenesis of pouchitis (see the key role of dysbiosis).
Some criticisms must be raised towards our systematic review. Its main limitation is that
only a small number of patients have been treated until now with vedolizumab for chronic
refractory pouchitis, but these data are of paramount importance for a condition with such a
high impact on quality of life. Furthermore, these patients had a history of severe chronic
illness, with lack of response to numerous treatment lines and previous surgical colectomy.
Another criticism arises by the fact that the definition of clinical improvement represents a
weak outcome, but the features of this extreme difficult-to-treat population and the
evidence of a 73.7% rate of endoscopic improvement reinforce these efficacy data of
vedolizumab. One important limitation of this systematic review is linked to the design of
the included studies (case reports and case series): no study using a comparison group was
found and a potential publication bias, due to lack of studies publishing negative results,
should be taken into account. Finally, given the small sample sizes, sub-analyses about
predictors of vedolizumab efficacy in this setting could not be undertaken.
In conclusion, our systematic review suggests that vedolizumab has significant efficacy in
chronic refractory or antibiotic-dependent pouchitis, also in patients who failed to respond
to other treatment modalities, including anti-TNF agents.
Larger studies with a higher number of patients are required to confirm these findings. A
phase-4 study aiming to evaluate the efficacy and safety of vedolizumab in the treatment of
chronic pouchitis (EARNEST) is already in progress.
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Table 1. Studies about the efficacy of vedolizumab in chronic refractory pouchitis
Author
Year
Type of study Age
Sex Anti-TNF for
pouchitis
Symptom improvement at
week 12
Endoscopic improvement within
week 24
Schmid et al. (16) 2017 Case report 54 M No Yes Yes
Coletta et al. (17) 2017 Case report 33 M Yes Yes Yes
Mir et al. (18) 2017 Case report 41 F No Yes Yes
Bär et al. (21)
2017 Case series 20
pts.
Median: 22.5
M: 12
F: 8
Yes: 11
No: 9
13 out of 20 9 out of 14
Martins et al. (19) 2018 Case report 20 F Yes Yes Yes
Orfanoudaki et al. (20) 2018 Case report 22 F Yes Yes Yes
Singh et al. (23)
2018 Case series 19
pts.
Median: 26.7
M: 10
F: 9
Yes: 9
No: 10
15 out of 19 14 out of 19
F: female; IPAA: ileal pouch-anal anastomosis; M: male; pts.: patients; TNF: tumor necrosis factor; ?: missing data.
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Fig. 1. Flow diagram of the study.
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Fig. 2. Clinical improvement of pouchitis 12 weeks after vedolizumab start.
15
Fig. 3. Endoscopic improvement of pouchitis within 6 months after vedolizumab start.
